Roger Chang
Internal Medicine · Lafayette, LANPI 1457937377
Payments from drug & device makers
Across 92 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$446
- Actelion Pharmaceuticals US, Inc.$298
- Merck$185
- Abiomed$147
- Boehringer Ingelheim$134
- Olympus America Inc.$130
- plus $795 from 16 others
What the payments were for
- Food & beverage$2,07397%
- Education$623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 23 | $446 |
| Actelion Pharmaceuticals US, Inc. | 13 | $298 |
| Merck | 9 | $185 |
| Abiomed | 1 | $147 |
| Boehringer Ingelheim | 5 | $134 |
| Olympus America Inc. | 2 | $130 |
| Melinta Therapeutics, LLC | 1 | $119 |
| Regeneron Healthcare Solutions, Inc. | 5 | $97 |
| Insmed, Inc. | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| La Jolla Pharmaceutical Company | 4 | $77 |
| GSK | 4 | $72 |
| Mallinckrodt Hospital Products Inc. | 4 | $71 |
| Sanofi | 3 | $56 |
| Exact Sciences | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $15 |
| Verona Pharma, Inc. | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,135 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 19 | $16,205 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $10,254 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,419 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 51 | $1,450 |
| Lamotrigine OdtLamotrigine | 14 | $1,177 |
| Atorvastatin Calcium | 50 | $685 |
| Gabapentin | 34 | $416 |
| Lisinopril | 55 | $405 |
| Hydralazine Hcl | 16 | $386 |
| Fluticasone Propionate | 16 | $315 |
| Carvedilol | 33 | $263 |
| Amlodipine Besylate | 40 | $263 |
| Omeprazole | 16 | $200 |
| Metoprolol Succinate | 20 | $196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $72 | $22,92640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Himani Reddy ManthenaLafayette$28K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.